Biomarin Pharmaceutical (BMRN) Other financing activities (2009 - 2025)

Biomarin Pharmaceutical's Other financing activities history runs 17 years deep, the most recent figure standing at $14.5 million for Q4 2025.

• Quarterly Other financing activities rose 83.92% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 70.66% YoY) and the FY2025 annual result came in at $14.5 million, down 70.66% from the prior year.
• Other financing activities was $14.5 million for Q4 2025 at Biomarin Pharmaceutical, up from $7.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $71.6 million in Q4 2023 and bottomed at -$52.4 million in Q3 2023.
• A 5-year average of $11.9 million and a median of $14.4 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities jumped 442.98% — and 2023, when it tumbled 464.81%.
• Biomarin Pharmaceutical's Other financing activities stood at -$33.3 million in 2021, then jumped by 176.53% to $25.5 million in 2022, then jumped by 181.12% to $71.6 million in 2023, then sank by 89.02% to $7.9 million in 2024, then surged by 83.92% to $14.5 million in 2025.
• Business Quant data shows BMRN's Other financing activities at $14.5 million in Q4 2025, $7.9 million in Q4 2024, and $4.8 million in Q3 2024.